CION Ameerpet
If your breast cancer is hormone receptor positive (ER/PR+), hormone therapy — also called endocrine therapy — can quietly lower your risk of the cancer coming back for years after surgery. About 70% of breast cancers are hormone-sensitive. Here a CION medical oncologist explains, in plain language, what these tablets do, why they are usually taken for 5 to 10 years, the side effects you may feel, and how our tumor board keeps you on track. Every first consultation is free.
Hormone therapy for breast cancer, more precisely called endocrine therapy, is treatment that stops the female hormones oestrogen and progesterone from feeding cancer cells. It is not the same as hormone replacement therapy (HRT) for menopause — in fact, it does the opposite.
It only helps one group of patients: those whose tumour is hormone receptor positive (ER+ and/or PR+). Roughly 70% of breast cancers are hormone-sensitive. We confirm this with an IHC (immunohistochemistry) report on your biopsy or surgical sample before we ever start. If your cancer is hormone-receptor negative or triple-negative, endocrine therapy will not work, and your CION tumor board will recommend a different path — we never prescribe a tablet that cannot help you.
Confirmed on your IHC pathology report. About 7 in 10 breast cancers qualify; hormone-negative tumours do not respond.
Most often given as adjuvant therapy after surgery and any chemo/radiation, to mop up hidden cells and cut recurrence.
Neoadjuvant endocrine therapy can shrink a tumour first, mainly in older or post-menopausal patients.
In metastatic ER+ breast cancer it can control the cancer for years, often with a targeted CDK4/6 inhibitor.
About 70% of breast cancers are hormone receptor positive (ER and/or PR positive), which means endocrine therapy can lower their risk of returning. Taking it for 5 years or more cuts recurrence by roughly 30% and reduces breast-cancer mortality by about 40% — protection that lasts well beyond the original treatment. Source: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) / NCCN.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Hormone-sensitive cancer cells carry receptors that grab oestrogen and use it as fuel to grow and divide. Endocrine therapy starves them in one of two ways, depending on your menopausal status and your tumour:
1. Block the receptor. Drugs like tamoxifen sit on the oestrogen receptor so oestrogen cannot dock — the fuel is present, but the cell cannot use it. 2. Lower the oestrogen. Aromatase inhibitors and ovarian suppression reduce how much oestrogen the body makes in the first place, so there is far less fuel available.
Which mechanism suits you depends largely on whether your ovaries are still producing oestrogen. That single question — pre-menopausal or post-menopausal — shapes the whole plan.
Ovaries still make most oestrogen, so we block the receptor (tamoxifen) and may also switch the ovaries off (suppression).
Ovaries are quiet; oestrogen comes from fat tissue via the aromatase enzyme — so aromatase inhibitors work best here.
Your tumour grade, nodes, age and other illnesses all feed into which drug class your tumor board chooses.
Starting a tablet is easy. Staying on it well for 5 to 10 years — with your bones, joints and peace of mind protected — is the hard part, and it is where outcomes are won or lost. That is what CION is built for.
With 150+ years of combined oncology experience, 17 super-specialist oncologists, and 35+ centres across Telangana and AP, your endocrine plan is decided by a tumor board — medical, surgical and radiation oncologists together — not a single opinion. Over 15,000+ patients have been treated, and we hold a 4.8/5 Google rating across centres. Our 1-year breast cancer survival is 96.9% versus the 85.4% national average*.
CION breast cancer 1-year survival: 96.9% vs national average 85.4% (+11.5%). *1-year survival. Source: ICMR / National Cancer Registry Programme (NCRP).
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Free first consultation for every cancer patient. Call us on 1800-202-8726 or request a callback today.
Three main approaches make up endocrine therapy. Many patients use one; some use them in combination or in sequence. Here is what each one is and who it usually suits — your oncologist will confirm what is right for you.
A daily tablet that blocks the oestrogen receptor. It works in both pre- and post-menopausal women, which makes it the usual first choice for younger patients. Because it does not switch oestrogen off completely, it carries a small added risk of blood clots and, rarely, changes in the uterine lining — so we review any unusual bleeding. Often given for 5 years, sometimes extended to 10.
Daily tablets that block the aromatase enzyme so the body makes less oestrogen. They only work in post-menopausal women (or pre-menopausal women whose ovaries have been suppressed). They tend to edge out tamoxifen on recurrence for post-menopausal patients, but the trade-off is joint stiffness and gradual bone thinning, so we add calcium, vitamin D and DEXA scans. No single one of the three is better than the others.
Monthly or 3-monthly injections that quiet the ovaries so they stop producing oestrogen, used in pre-menopausal women — usually alongside tamoxifen or an aromatase inhibitor for higher-risk cases. The effect is reversible when the injections stop. Surgery to remove the ovaries is a permanent alternative some women choose.
Common plans include tamoxifen for 2-3 years then an aromatase inhibitor, or an aromatase inhibitor from the start. In advanced ER+ disease, endocrine therapy is paired with a targeted CDK4/6 inhibitor. The right sequence depends on menopausal status, side-effect tolerance and recurrence risk — decided by your tumor board.
This surprises many patients: surgery and chemo finish in months, but the tablet continues for years. There is a clear reason. Hormone-receptor-positive breast cancer can return late — sometimes 5, 10 or even 15 years after the original diagnosis — because a few hidden cells can stay quiet for a long time. Endocrine therapy keeps the fuel switched off through that whole risky window.
The evidence is strong: taking endocrine therapy for 5 years or more greatly reduces the risk of recurrence and of dying from breast cancer. Across hormone-receptor-positive patients, it cuts recurrence risk by roughly 30% and reduces mortality by about 40%. For patients at higher risk, your oncologist may recommend extending to 10 years for further protection. The minimum that delivers this benefit is 5 years — which is exactly why finishing the course matters so much.
Most patients tolerate endocrine therapy far better than chemotherapy, but side effects are real and are the main reason people stop early. At CION we treat side effects as part of the plan — reviewed at every visit, not something you should just put up with. Tell us, and we adjust.
The most common effect of both tamoxifen and aromatase inhibitors. They often ease with time. We can advise on lifestyle measures, the timing of your dose, and non-hormonal medicines where needed — never HRT, which would undo the treatment.
Especially with aromatase inhibitors — in fact arthralgia is the single biggest reason patients stop. Gentle exercise, pain relief, vitamin D, and sometimes switching to a different aromatase inhibitor or to tamoxifen usually brings it under control. Do not stop the tablet on your own first.
Aromatase inhibitors can gradually weaken bone. We monitor with DEXA scans, prescribe calcium and vitamin D, and add bone-strengthening medicine if needed — so a manageable side effect does not become a fracture.
Low mood, irritability and tiredness can occur. Our psycho-oncology support, sleep advice and dose-timing tweaks help. You are not imagining it, and you are not alone in it.
Common and rarely discussed — but very treatable with non-hormonal options. We raise it so you do not have to. It should not be a reason to suffer in silence or to quit therapy.
Tamoxifen carries a small added risk of blood clots and, rarely, changes in the uterine lining. Report any leg swelling, breathlessness or unusual vaginal bleeding promptly — we investigate quickly. For most women the benefit far outweighs these uncommon risks.
A tablet only protects you if you keep taking it. Studies show adherence falls over time — from around 87% in year 1 to roughly 50% by year 5 in some groups — and that stopping early raises the risk of the cancer coming back and lowers survival. Side effects, especially joint pain, are the usual trigger.
This is the gap most information pages ignore, and it is exactly where CION focuses. We do not just hand over a prescription. We schedule regular reviews, treat side effects actively, switch drugs when one does not suit you, and keep you informed about why the next year of tablets still matters. If you are struggling on your current hormone tablet — even one started elsewhere — talk to us before you stop. Often a small change keeps you protected.
Hear from patients who completed their endocrine therapy with our side-effect and bone-health support behind them.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.Most patients take endocrine therapy for at least 5 years after surgery. For those at higher risk of recurrence, your oncologist may recommend extending it to 10 years for additional protection. Hormone-receptor-positive breast cancer can come back many years after the original diagnosis, so the tablet keeps oestrogen switched off through that long risk window. Five years is the minimum shown to meaningfully reduce recurrence and improve survival, which is why completing the full course your doctor advises is so important. In advanced or metastatic disease, treatment may continue for as long as it keeps the cancer controlled.
No. Hormone (endocrine) therapy only works if your tumour is hormone receptor positive - ER positive and/or PR positive. About 70% of breast cancers are hormone-sensitive. We confirm your status with an IHC report on your biopsy or surgery sample before prescribing anything. If your cancer is hormone-receptor negative or triple-negative, these tablets will not help, and our tumor board will recommend a more suitable treatment such as chemotherapy, targeted therapy or immunotherapy. At CION we never prescribe a treatment that cannot benefit your specific cancer.
Tamoxifen blocks the oestrogen receptor on cancer cells, so oestrogen cannot reach them; it works in both pre- and post-menopausal women. Aromatase inhibitors (anastrozole, letrozole, exemestane) lower the amount of oestrogen the body makes and only work in post-menopausal women, or in pre-menopausal women whose ovaries have been suppressed. For post-menopausal patients, aromatase inhibitors often reduce recurrence slightly more, but they can cause joint stiffness and bone thinning, while tamoxifen carries a small added risk of blood clots. Your tumor board chooses based on your menopausal status, risk and how you tolerate side effects.
The most common side effects are hot flushes, night sweats, joint and muscle aches, fatigue, mood changes, vaginal dryness and reduced libido. Aromatase inhibitors are linked to joint pain and gradual bone thinning; tamoxifen carries a small risk of blood clots and uterine-lining changes. Almost all of these are manageable. At CION we monitor bone density with DEXA scans, prescribe calcium and vitamin D, offer non-hormonal relief for hot flushes, and provide psycho-oncology support for mood. If one drug does not suit you, switching to another often solves the problem - so you stay protected without suffering.
Stopping endocrine therapy before your doctor advises raises the risk of the cancer returning and lowers long-term survival - the protection only lasts while you take it. Studies show many patients quit early, usually because of joint pain or other side effects, with adherence falling to around 50% by year 5 in some groups. The good news is that side effects can almost always be managed, and switching to a different drug often helps. If your current tablet is bothering you - even one started at another hospital - speak to a CION oncologist before stopping. A small change usually keeps you on track.
Some patients do notice weight gain or find it harder to lose weight on endocrine therapy, and hot flushes, fatigue and mood changes can make staying active harder. The effect varies a lot from person to person and is usually modest. Regular gentle exercise, a balanced diet and support from our nutritionist help keep weight stable and also ease joint stiffness and fatigue. If weight or other side effects are affecting your daily life, tell your oncologist - it is part of what we review at every visit, and there are practical steps we can take together rather than stopping a treatment that is protecting you.
It depends on your cancer. Hormone therapy and chemotherapy do different jobs. Chemotherapy is used when the cancer is more aggressive or higher risk, often given in months; endocrine therapy targets hormone-receptor-positive cancer specifically and is taken for years to prevent recurrence. Many patients with ER/PR-positive cancer have surgery, then chemotherapy and/or radiation, and then start hormone therapy as long-term protection. Some lower-risk patients may need endocrine therapy without chemotherapy at all. Genomic tests can help decide. Your CION tumor board reviews all of this together so you get exactly the treatment your cancer needs - and no more.
Yes. CION Cancer Clinics manages endocrine therapy for breast cancer across 35+ centres in Telangana and Andhra Pradesh, led by senior medical oncologists and reviewed by a tumor board. We confirm your ER/PR status, recommend the right drug, and - just as importantly - manage side effects and bone health for the full 5 to 10 years so you stay on treatment comfortably. We welcome patients who started therapy elsewhere and need better side-effect support. Your first consultation is free and lasts a full 45 minutes. Call 1800-202-8726 or request a callback to book.